Director

Prof. Dr. Nikolaus Weiskopf
Managing Director

Phone: +49 341 9940-133
Fax: +49 341 9940-2448
Email: weiskopf@cbs.mpg.de

Homepage

BRAINTRAIN will improve and adapt the methods of real-time fMRI neurofeedback (fMRI-NF) for clinical use, including the combination with electroencephalography (EEG) and the development of standardised procedures for the mapping of brain networks that can be targeted with neurofeedback.

Braintrain

BRAINTRAIN will improve and adapt the methods of real-time fMRI neurofeedback (fMRI-NF) for clinical use, including the combination with electroencephalography (EEG) and the development of standardised procedures for the mapping of brain networks that can be targeted with neurofeedback.
The goal of the ERC project is to develop novel methods for high-resolution quantitative magnetic resonance imaging (MRI) at 3T-9.4T to reliably characterize and quantify the detailed microstructure of the human cortex. This ambitious goal of developing in vivo histology using MRI (hMRI) can only be achieved by an integrative approach combining innovations in MR physics, modelling and tailored neuroscience experiments. If successful, the project will transform research and clinical imaging. It will facilitate personalized medicine, patient stratification and multi-center treatment trials in neurodegenerative diseases by providing reliable and standardized biomarkers.

hMRI: Non-Invasive In-Vivo Histology in Health and Disease Using Magnetic Resonance Imaging (MRI)

The goal of the ERC project is to develop novel methods for high-resolution quantitative magnetic resonance imaging (MRI) at 3T-9.4T to reliably characterize and quantify the detailed microstructure of the human cortex. This ambitious goal of developing in vivo histology using MRI (hMRI) can only be achieved by an integrative approach combining innovations in MR physics, modelling and tailored neuroscience experiments. If successful, the project will transform research and clinical imaging. It will facilitate personalized medicine, patient stratification and multi-center treatment trials in neurodegenerative diseases by providing reliable and standardized biomarkers.
Spinal cord injury is a severe and devastating neurological disorder that leaves patients with permanent paralysis of the body. No treatment is available today to regenerate interrupted nerve fibers and repair the damaged spinal cord. The EU Horizon 2020 collaborative NISCI project is a multi-center clinical proof of concept trial aiming at the repair of the injured spinal cord through antibody induced regeneration after acute spinal cord injury. The biomarker subproject at the MPI CBS is an international collaboration between the Prof. Weiskopf (MPI-CBS) and Dr. Freund (University of Zuerich), bringing together the unique expertise in MRI methods and clinical neuroscience. We will be developing and deploying state-of-the-art quantitative MRI methods for characterization of the brain and spinal cord microstructure. This includes deploying the MRI techniques across the different clinical trial sites and ensuring their high performance. These methods will serve as a sensitive biomarker for treatment effects and potential adverse effects of the antibody treatment.

NISCI: Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury, a multicenter European clinical proof of concept trial

Spinal cord injury is a severe and devastating neurological disorder that leaves patients with permanent paralysis of the body. No treatment is available today to regenerate interrupted nerve fibers and repair the damaged spinal cord. The EU Horizon 2020 collaborative NISCI project is a multi-center clinical proof of concept trial aiming at the repair of the injured spinal cord through antibody induced regeneration after acute spinal cord injury. The biomarker subproject at the MPI CBS is an international collaboration between the Prof. Weiskopf (MPI-CBS) and Dr. Freund (University of Zuerich), bringing together the unique expertise in MRI methods and clinical neuroscience. We will be developing and deploying state-of-the-art quantitative MRI methods for characterization of the brain and spinal cord microstructure. This includes deploying the MRI techniques across the different clinical trial sites and ensuring their high performance. These methods will serve as a sensitive biomarker for treatment effects and potential adverse effects of the antibody treatment.
 
loading content